REVVITY, INC. 10-Q Summary: Q2 2024
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2024. Revvity, Inc. operates as a leading provider of health science solutions with two primary reportable segments: Life Sciences (products and services for life sciences customers) and Diagnostics (clinically-oriented tools for reproductive health, emerging market diagnostics, and applied genomics). The company completed the sale of its Applied, Food, and Enterprise Services businesses in March 2023, which are now reported as discontinued operations.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $691.7 million | $709.1 million | $1,341.6 million | $1,383.9 million |
| Gross Margin | 55.7% | 56.7% | 55.2% | 56.6% |
| Operating Income | $85.7 million | $78.1 million | $129.8 million | $154.2 million |
| Operating Margin | 12.4% | 11.0% | 9.7% | 11.1% |
| Net Income (Continuing Ops) | $72.6 million | $58.6 million | $101.3 million | $83.5 million |
| Net Income (Total) | $55.4 million | $35.6 million | $81.4 million | $605.0 million |
| Diluted EPS (Total) | $0.45 | $0.28 | $0.66 | $4.80 |
| Cash & Equivalents | $1,248.1 million | Balance Sheet Data | ||
| Total Debt (Carrying Value) | $3,874.0 million | Balance Sheet Data | ||
| Operating Cash Flow (YTD) | $332.5 million | $28.0 million | YTD Comparison |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 2% in Q2 and 3% YTD compared to the prior year. The Life Sciences segment saw a 7% revenue decline driven by lower reagents and instruments sales due to market headwinds. The Diagnostics segment grew 1%, driven by immunodiagnostics and reproductive health, offset by a decline in applied genomics.
- Margin Compression: Gross margins decreased 101 basis points in Q2 (to 55.7%) and 143 basis points YTD (to 55.2%) due to lower sales volume and increased material costs, partially offset by pricing actions and productivity gains.
- Operating Income Growth: Despite revenue declines, operating income increased 10% in Q2 and decreased 16% YTD. Q2 operating margins improved to 12.4% from 11.0% in the prior year due to cost containment and productivity initiatives.
- Discontinued Operations Impact: The prior year YTD net income of $605.0 million included a significant gain from the sale of the Applied, Food, and Enterprise Services businesses. Current period results reflect a loss from discontinued operations of $19.9 million YTD, primarily due to adjustments to receivables and divestiture costs.
- Expense Management: SG&A expenses decreased 6% in Q2 and 1% YTD. R&D expenses decreased 16% in Q2 and 14% YTD, driven by cost containment and reduced stock compensation related to the BioLegend acquisition.
Guidance, Outlook, and Risks
- Outlook: Management expects the effective tax rate on continuing operations to be approximately 20% for fiscal year 2024. No specific revenue or earnings guidance was provided in this text.
- Liquidity: The company holds $1,248.1 million in cash and cash equivalents and has $1.5 billion available under its revolving credit facility. It holds $706.1 million in U.S. Treasury securities intended to repay $711.5 million in notes maturing in September 2024.
- Capital Allocation: The company repurchased $25.8 million of stock YTD under a $600 million program (with $329.6 million remaining). Quarterly dividends of $0.07 per share were declared for Q2 and Q3 2024.
- Risks: Key risks include global economic conditions affecting customer demand, supply chain disruptions, foreign currency fluctuations, and the potential impairment of significant intangible assets ($9.3 billion net). The company also faces contingent consideration obligations of up to $80.9 million related to acquisitions.
Investor Verification Checklist
- Debt Maturity: Verify the execution of the repayment plan for the $711.5 million in 2024 Notes using the designated U.S. Treasury securities.
- Discontinued Operations: Monitor the receipt of the remaining "Brand Fee" installments (approx. $65.6 million remaining) and the valuation of the $150 million contingent consideration from the 2023 divestiture.
- Intangible Assets: Review the $9.3 billion in net intangible assets for potential impairment risks given the revenue headwinds in the Life Sciences segment.
- Segment Mix: Track the divergence between the declining Life Sciences segment and the growing Diagnostics segment to assess long-term portfolio strategy.
- Working Capital: Analyze the $30.4 million net cash decrease in working capital YTD to ensure inventory and receivables management remains efficient.